Summer Seminars and Institutes for Higher Education Faculty
The National Endowment for the Humanities (NEH) Division of Education Programs is accepting applications for the Summer Seminars and Institutes for Higher Education Faculty program. The purpose of this program is to provide higher education faculty across the nation the opportunity to broaden and deepen their engagement with the humanities. The one- to four-week professional development programs allow participants to explore recent developments in scholarship, teaching, and/or curriculum through study of a variety of humanities topics.
Funding Agency: National Endowment for the Humanities
Deadline: March 3, 2020
Amount: $235,000
For more information: https://www.neh.gov/grants/education/summer-seminars-and-institutes-higher-education-faculty
Summer Seminars and Institutes for K-12 Educators
The National Endowment for the Humanities (NEH) Division of Education Programs is accepting applications for the Summer Seminars and Institutes for K-12 Educators program. The purpose of this program is to provide school teachers across the nation the opportunity to broaden and deepen their engagement with the humanities. One- to four-week residential programs, led by scholars and K-12 professionals, allow participants to study a variety of humanities topics. Seminars and Institutes emphasize the intellectual quality of humanities education and address recent developments in scholarship, teaching, and/or curriculum.
Funding Agency: National Endowment for the Humanities
Deadline: March 3, 2020
Amount: $235,000
For more information: https://www.neh.gov/grants/education/summer-seminars-and-institutes-k-12-educators
Infrastructure for the Expansion of Rhesus macaque Colonies to Support HIV/AIDS-related Research (C06 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications from qualified research institutions to seek funds to develop or improve the physical infrastructure of nonhuman primate (NHP) facilities, focusing on the needs related to the expansion of Rhesus macaque colonies. These infrastructure needs include additional space required for breeding and housing of animals as well as research facilities for carrying out HIV/AIDS-related studies linked to the expansion of the colonies. These NHP facilities must support research aligned with the NIH-established priorities for HIV/AIDS research. Any request must be justified by current and anticipated future research needs.
Funding Agency: National Institutes of Health
Deadline: March 6, 2020
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-087.html
Radiobiology of High Linear Energy Transfer (High LET) Exposure in Cancer Treatment (R01, Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research projects that examine the relative biological effectiveness (RBE) of high linear energy transfer (high LET) radiation on cell and tissue targets. The overall goal of the research is to establish a firm scientific basis for RBE models of high LET radiation and determine potential benefits in cancer treatment. A meritorious application is expected to be well-balanced in terms of interdisciplinary science that spans approaches in both radiation biology and radiation physics research. Priorities for this FOA are on 1) Applications with potential to enhance the understanding of mechanisms related to high LET effects in both cancer and normal tissues; and 2) Characterization of high LET effects that have potential to inform treatment strategies for cancers resistant to conventional radiation or other combined modality treatments.
Funding Agency: National Institutes of Health
Deadline: March 19, 2020
Amount: $499,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-032.html
MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)
The purpose of this FOA is to invite additional applications for the Preclinical Animal Study Sites (PASS) as part of the Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC) (http://commonfund.nih.gov/MolecularTransducers). Awards made through this FOA will support preclinical mechanistic studies on a range of molecular compounds identified in the initial PASS exercise protocol (RM 15-013) which was designed to complement and substantially expand the data from the human clinical study. This FOA is expected to support up to 4-6 additional PASS as part of the MoTrPAC consortium. Phase 2 of the original PASS study sites will design and conduct detailed mechanistic studies to identify the sources, signaling pathways, physiological targets, and functions of mobilized and identified molecular transducers of physical activity; to recognize feedback and interaction effects among different pathways and tissues; and to discover specific roles of the molecules associated with specific health benefits. This RFA calls for additional proposals to explore the mechanistic links between the candidate molecular transducers of physical activity and functional effects of exercise in tissues. Overall, data from the PASS studies are anticipated to substantially increase our understanding of how different tissues and organs adapt to the exercise induced changes. The PASS will serve to confirm human data and extend the analyses of candidate transducers of physical activity from the clinical study across multiple organs and tissues that are not accessible from human participants. Applicants should propose what they think is the best strategy and approach for investigating how these mobilized compounds synergize to coordinate the overall homeostatic response to exercise. Final decisions on the actual compounds for future screening will be determined in consultation with the MoTrPAC Steering Committee.
Funding Agency: National Institutes of Health
Deadline: March 20, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-009.html
Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites qualified academic institutions to apply for support to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and nonprofit private institutions of higher education. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. The proposed project must serve the applicant-defined institution-wide biomedical research needs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted are the modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.
Funding Agency: National Institutes of Health
Deadline: March 17, 2020
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-086.html
Mendelian Genomics Research Centers (U01 Clinical Trial Optional)
The purpose of this Funding Opportunity is to establish a consortium aimed at significantly increasing the proportion of Mendelian conditions with an identified genetic cause. A key objective of the Mendelian Genomics Research Centers is to develop and apply approaches to discover causal genes underlying Mendelian conditions for which a candidate gene was not identified using whole exome sequencing alone.
Funding Agency: National Institutes of Health
Deadline: April 15, 2020
Amount: $2,000,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-007.html
New/Unconventional Animal Models of Alzheimers Disease (R24 Clinical Trial Not Allowed)
This funding opportunity announcement (FOA) invites research to develop, characterize, and validate new, unconventional, or innovative non-rodent mammalian models of late-onset (sporadic) Alzheimer’s Disease (AD). These new models are expected torecapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive hallmarks and aspects of late-onset AD.Research supported under this FOA is expected to provide new investigativetools to identify the gaps in current knowledge related to molecular mechanisms of late-onset AD and identify potential therapeutic targets.
Funding Agency: National Institutes of Health
Deadline: October 7, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-003.html
Central and Peripheral Control of Balance in Older Adults (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invitesapplications that propose basic and/or clinical studies to investigate central and peripheral control of balance in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which when impaired contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological,and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults.
Funding Agency: National Institutes of Health
Deadline: October 2, 2020
Amount: $500,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-011.html
Novel Approaches to Advance Coordinated Registry Networks (CRNs) (U01 Clinical Trial Optional)
Recently FDA launched a series of strategic efforts designed to improve the national capacity to study use and impact of medical devices in the real-world setting. FDA is collaborating with medical device stakeholders to build the National Evaluation System for health Technology (NEST) NEST will support the sustainable generation and use of timely, reliable, and cost-effective Real-World Evidence (RWE) by leveraging clinical registries in addition to the other data sources such as electronic health records (EHRs), pharmacies, public and private claims, and patient-generated data. Since in the world of medical devices today, clinical registries collect and maintain detailed, curated clinical data on millions of patients receiving diagnostics and treatments involving health technologies, they can provide critical infrastructure that can be used for a variety of analyses related to real-world patient care and outcomes. To address some of the inherent and modifiable limitations of the registries, the model of strategically Coordinated Registry Networks (CRNs) was recommended by the National Medical Device Registry Task Force (NMDRTF) and further developed by Medical Device Epidemiology Network (MDEpiNet). Following the recommendations of the NMDRF, several CRNs have been rapidly developing. More recently MDEpiNet launched the CRN Community of Practice (COP), a partnership of national registries aspiring to evolve into CRNs, that engages a wide variety of stakeholders to ensure that high value data is generated by CRNs including patient organizations, health care providers, regulators, payors, health services researchers, health technology manufacturers, software vendors, health exchanges and local, state, national and international government agencies and could also be used in social determinants of health and other local and state initiatives. This learning community, coordinated by MDEpiNet Coordinating Center (MDEpiNetcc), uniquely integrates multi-stakeholder’s views and patient perspectives with harmonization and interoperability to address an important unmet need in the country, especially for conducting research on conditions and treatments that though clinically valuable, require continued evaluation of safety and effectiveness evidence as it evolves throughout the total product life cycle. The main goal of this FOA is to advance infrastructure and methodology research to promote evolution of traditional registries into mature CRNs contributing a reliable, relevant and timely data on health technologies. Specific Aims are: (1) Facilitate coordination and maturation of Coordinated Registry Networks (CRN) Community of Practice; (2) Develop and test drive novel methods in CRN science and surveillance by leveraging big data analytics; (3) Augment CRNs by linking registries to other data sources (including administrative claims, electronic health records, patient generated data, and other available data sources; (4) Collaborate with NEST partners and others to advance capacity of FDA to address complex health technology-related questions. This will result in a more strategic approach to addressing the needs of the entire patient-centered medical device ecosystem, via harmonized and interoperable infrastructure that will allow for more complex study designs and analyses. Capturing standardized data will streamline data collection and support exchange of data across therapies, patient populations and episodes of care. For example, by including Unique Device Identification (UDI) in the CRN minimum core data set, the CRNs become suitable for routinely studying device-specific questions; by including patient-generated data in CRN, the research community can link the patient experiences to clinical data sources and regulators can identify how devices are performing for patients and identify patient-centric endpoints for future studies; and by linking registry data to additional data sources (such as medical claims submitted by providers to bill for medical services), patients and providers can have a more comprehensive understanding of long-term outcomes and adverse events associated with health technologies that are important for reaching informed decisions. All applications developed to address this announcement should consider the following points: 1. The existing CRN Community of Practice (COP) should continue to support transparency such that patients, physicians, hospitals, insurers, medical device industry, and regulatory bodies will have access to and be able to replicate any given analysis; 2. Applications should leverage the existing partnerships to advance data access and availability to all stakeholders and partners, including FDA (for research purposes as well as for Total Product Life Cycle evaluation); 3. Applications should include details on how patient privacy and data security will be established and maintained; 4. Applications should incorporate use of Unique Device Identification (UDI) to allow for adequate tracking and investigation into potential postmarket signals; 5. The methods and infrastructure systems developed should be capable of being applied more broadly across the medical device landscape; 6. Methodology and infrastructure development efforts should address the needs of multiple CRNs and their stakeholders across clinical areas; and 7. The scientific plan for developing the CRNs should be accompanied by a plan or framework for establishing a sustainable partnership business infrastructure to allow for substantial national or international coverage over an extended period.
Funding Agency: Food and Drug Administration
Deadline: March 16, 2020
Amount: $3,000,000
For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-20-021.html
Mendelian Genomics Data Coordinating Center (U24 Clinical Trial Not Allowed)
The purpose of this FOA is to solicit applications to develop and implement a Mendelian Genomics Data Coordination Center (MGDCC) for the Mendelian Genomics Research Consortium. The MGDCC will be responsible for managing the release of data and findings generated under the program, as well as program outreach, ensuring maximum utility for the research community. The MGDCC will also coordinate program logistics, supporting effective working groups and meetings. Finally, the MGDCC will oversee the programs Opportunity Fund, providing rapid turnaround short-term funding for functional follow-up studies to program findings.
Funding Agency: National Institutes of Health
Deadline: April 15, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-008.html
Public Health and Health Systems Partnerships to Increase Colorectal Cancer Screening in Clinical Settings
This announcement provides funds to recipients to partner with health systems and individual primary care clinics to implement evidence-based interventions (EBIs) to increase colorectal cancer (CRC) screening uptake among applicant defined populations age 50-75 years that have CRC screening rates lower than the national, regional, or local rate. Recipients will: 1) establish partnerships with health systems and primary care clinics to implement at least two of four EBIs recommended in The Community Guide (client reminders; provider reminders, reduction of structural barriers, and provider assessment and feedback); 2) establish partnerships with organizations that provide expertise to support the implementation of EBIs in primary care clinics; 3) conduct a formal assessment of each clinics capacity/readiness to implement EBIs; 4) utilize the clinic assessment to select appropriate EBIs to implement; 5) provide resources to partner clinics to provide and support completion of follow-up colonoscopies after a positive or abnormal screening test; and 6) collect and submit high-quality clinic-level data including baseline and annual CRC screening rates.
Funding Agency: Centers for Disease Control – NCCDPHP
Deadline: March 17, 2020
Amount: $900,000
For more information: Go to grants.gov and search opportunity # CDC-RFA-DP20-2002
NIAMS Clinical Trial Planning Grant (R34) – Clinical Trial Not Allowed
This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to permit the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant is recommended prior to submission of an application through a U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should be intended to support trials that are hypothesis-driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS.
Funding Agency: National Institutes of Health
Deadline: November 1, 2022
Amount: $250,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-090.html
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed)
The purpose of the initiative is to support multidisciplinary research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
Funding Agency: National Institutes of Health
Deadline: April 1, 2022
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-088.html
Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21- Clinical Trial Not Allowed)
The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
Funding Agency: National Institutes of Health
Deadline: April 1, 2022
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-081.html
Office of Postsecondary Education (OPE): Undergraduate International Studies and Foreign Language (UISFL) Program CFDA Number 84.016A
Note: Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on February 13, 2019 (84 FR 3768),or at www.govinfo.gov/content/pkg/FR-2019-02-13/pdf/2019-02206.pdf. Purpose of Program: The UISFL program provides grants for planning, developing, and carrying out projects to strengthen and improve undergraduate instruction in international studies and foreign languages in the United States. Catalog of Federal Domestic Assistance (CFDA) number 84.016A
Funding Agency: Department of Education
Deadline: March 24, 2020
Amount: $120,000
For more information: https://www.govinfo.gov/content/pkg/FR-2020-01-14/pdf/2020-00374.pdf
OVW FY 2020 Research and Evaluation Initiative
The purpose of the Office on Violence Against Women (OVW)’s Research and Evaluation (R&E) Initiative is to research and evaluate approaches to combating domestic/dating violence, sexual assault, and stalking. By generating more knowledge about strategies for serving victims and holding offenders accountable, communities that benefit from Violence Against Women Act (VAWA) funding will be better equipped to align their work with practices that are known to be effective, and they will be more capable of generating empirical knowledge on the efficacy of new and promising ways of doing things. R&E is designed to support researcher-practitioner partnerships and a broad range of methods, including qualitative, mixed-method, and quasi-experimental designs.
Funding Agency: Office on Violence Against Women
Deadline: March 25, 2020
Amount: $450,000
For more information: https://www.justice.gov/ovw/page/file/1234906/download
Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.
Funding Agency: National Institutes of Health
Deadline: May 24, 2022
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-093.html
Medications Development for the Treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the Combination of AUD and AROD (U01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds through the drug development pipeline for the treatment of Alcohol Use Disorder (AUD) or Alcohol-Related Organ Damage (AROD), or the combination of AUD and AROD.
Funding Agency: National Institutes of Health
Deadline: March 26, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-20-007.html
Drug Development Tools Research Grants (U01 Clinical Trial Optional)
Drug development tools (DDTs) are methods, materials, or measures that can potentially facilitate drug development. To support DDT development efforts, FDA established qualification programs for animal models for use under the Animal Rule, biomarkers, and clinical outcome assessments. Examples of DDTs may include but are not limited to: a biomarker used for clinical trial enrichment, a clinical outcome assessment (COA) used to evaluate clinical benefit, or an animal model used for efficacy testing of medical countermeasures under the regulations commonly referred to as the Animal Rule. Qualification is a conclusion that within the stated context of use, the DDT can be relied upon to have a specific interpretation and application in drug development and regulatory review under the FD&C Act. Qualification does not encompass the use of a DDT outside the Context of Use (COU) specified through the qualification process. Once qualified, a DDT may be used within the qualified COU as part of any relevant drug or biologic Investigational New Drug Application (IND), New Drug Application (NDA) or Biologic Licensing Application (BLA) without submission of additional information to justify the use of the DDT. Qualification of a DDT is voluntary, and the use of a qualified DDT is not required for drug or biologic development. However, having qualified DDTs that can be used by multiple sponsors helps optimize drug development and evaluation. Increased public availability of qualified DDTs for specific contexts of use is anticipated to benefit the public health through (1) increased availability of effective drugs, (2) earlier access to medical therapies and (3) an enhanced knowledge of the drug under development. The qualification process allows for greater efficiency of development of DDTs by promoting DDT development in the precompetitive arena through collaborative efforts such as public-private partnerships and consortia. These grants will be used to provide funding to developers of drug development tools that have an accepted Letter of Intent (LOI) within CDER/CBER’s Drug Development Tool Qualification Program and are working towards to next qualification submission as described here: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm378219.htm. The grants will be used to further the development of tools that, once qualified, will be made publicly available to fill unmet needs in drug development. Applicants should use the outline of the Qualification Plan (QP) or Full Qualification Package (FQP) of the respective DDT program they are in, to assist in developing their grant application. Funding will only support grantee’s work towards either their qualification plan or full qualification package.
Funding Agency: Food and Drug Administration
Deadline: March 17, 2020
Amount: $250,000
For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-20-009.html
NIMH Research Education Programs for Psychiatry Residents (R25- Independent Clinical Trial Not Allowed)
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.
Funding Agency: National Institutes of Health
Deadline: May 25, 2022
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-094.html
Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional)
This FOA invites applications for Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (hereafter termed “Fragile X Centers”). Successful Centers will be composed of multidisciplinary teams of investigators collaborating to address specific research priorities identified in the Strategic Plan.
Funding Agency: National Institutes of Health
Deadline: April 3, 2020
Amount: $1,300,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-20-003.html
Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important and have not received sufficient attention. Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ
Funding Agency: National Institutes of Health
Deadline: November 17, 2020
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-005.html
Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (U19 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) solicits applications to establish Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (CARBIRUs) focused on improving our understanding of bacterial and host factors important for antibacterial resistance and infection to inform development of new approaches to prevent, diagnose, and treat antibacterial-resistant infections.
Funding Agency: National Institutes of Health
Deadline: May 8, 2020
Amount: $1,500,000
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-001.html
NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed)
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Funding Agency: National Institutes of Health
Deadline: May 25, 2022
Amount: $200,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-080.html
KUH Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
The purpose of the Kidney, Urology or Hematology (KUH) Predoctoral to Postdoctoral Fellow Transition Awards (F99/K00) is to recruit exceptional graduate students from diverse research fields to pursue postdoctoral training focused on Kidney, Urology or Hematology (K, U, or H) research. Talented graduate students from disciplines including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics are invited to apply to this opportunity. Graduate students who are already involved in K, U, or H research are not eligible for the F99/K00 award and are instead encouraged to apply for the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31, PA-19-195). Prospective applicants are strongly encouraged to contact the NIDDK Program Official prior to initiating plans for application submission. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Agency: National Institutes of Health
Deadline: March 2, 2021
For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-032.html
Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.
Funding Agency: National Institutes of Health
Deadline: January 25, 2023
Amount: $300,000
For more information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-095.html